

# Natural beauty and wellness for the world



mal use only

# 1H FY22 Results Presentation



**Dave Fenlon**  
Group CEO & Managing  
Director

**Efee Peell**  
Group CFO

**Rory Gration**  
Group COO  
*Group CEO & Managing  
Director from 1 March 2022*

Friday 25 February 2022

# Disclaimer



This presentation has been prepared by BWX Limited ACN 163 488 631 (BWX). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context.

The information contained in this presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this presentation, BWX has not considered the objectives, financial position or needs of any particular recipient. BWX strongly suggests that investors consult a financial advisor prior to making an investment decision. This presentation is strictly confidential and is intended for the exclusive benefit of the institution to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of BWX. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of BWX, its related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation.

This presentation may include “forward looking statements”. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guidance” and other similar expressions. Indications of, and guidance on, future earnings or dividends and financial position and performance are also forward looking statements. These forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BWX and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in those statements. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward looking statements and BWX assumes no obligation to update that information.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities and neither this presentation nor anything contained in it forms the basis of any contract or commitment.

# Executive Summary



## STRONG 1H22 REVENUE & EBITDA

- Statutory Revenue increased 22.3% vs pcp to \$103.4m in 1H22
- Statutory NPAT decreased vs pcp to -\$2.3m in 1H22
- Underlying Revenue increased 26.5% vs pcp to \$106.9m<sup>1</sup> in 1H22 (\$107.1m constant currency<sup>2</sup>)
- EBITDA increased 26.2% vs pcp to \$14.3m<sup>3</sup> in 1H22
- Underlying NPAT increased 22.1% vs pcp to \$4.7m<sup>3</sup> in 1H22



## STRATEGIC EXECUTION CONTINUES TO BE A KEY PRIORITY

- Points of distribution globally in line with expectations at 1.6 million at 1H22 (+21% vs pcp) and on track to achieve 2+ million target by end FY22
- Clayton Facility commencing manufacturing in April, on track to deliver 300bps margin expansion in line with business case
- Three-year growth strategy agreed for Go-To Skincare; commencing 2H22
- Direct-to-consumer revenues represented 41% of 1H22 revenue – ahead of previously stated target of 38% by FY23



## PERFORMANCE WEIGHTED TO 2H WITH MORE GROWTH TO UNLOCK

- BWx anticipates strong underlying revenue and EBITDA growth in full-year FY22 with performance weighted to 2H as per previous years, however, BWx continues to closely monitor the external COVID-impacted trading environment
- Growth potential to be unlocked through an expanded brand portfolio and delivery of omnichannel distribution gains in key regions
- Clayton Facility will enable a step change in financial and operational performance as BWx continues to reinvest cost savings back into its brands to support longer-term value creation



**(1)** Includes 6-month contribution of Flora & Fauna (acquired 01/07/21) and 3-month contribution of Go-To Skincare (acquired 30/09/21). It excludes the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense (refer slide 8 for reconciliation to statutory results). **(2)** Constant currency excludes FX translation impact from USD, GBP, CAD, EUR. **(3)** non-IFRS measures that exclude \$3.0m of one-off Acquisition-Related Expenses and the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense.

# Agenda



- Purpose
- Performance Highlights
- Financial Summary
- Strategy & Outlook
- Appendix

NATURAL  
BEAUTY AND  
WELLNESS  
FOR THE  
WORLD

BWX is proudly a **purpose-driven company**. We exist to **democratise Natural**. Our growing portfolio of brands and platforms **empower consumers** to make **conscious choices** to support their health and the health of our planet.

OUR PURPOSE

LUXURY / PREMIUM

(Partially Price Determined)

NATURAL LED



MASS

(Partially Price Determined)

GO-TO



ANDALOU  
NATURALS



SCIENTIFIC / CLAIMS LED

not for personal use only

# Financial Highlights



|                                  | Statutory Revenue | Underlying Revenue <sup>(1)</sup> | EBITDA <sup>(2)</sup> | Underlying NPAT <sup>(2)</sup> | Statutory NPAT              |
|----------------------------------|-------------------|-----------------------------------|-----------------------|--------------------------------|-----------------------------|
| 1H22                             | \$103.4m          | \$106.9m                          | \$14.3m               | \$4.7m                         | -\$2.3m                     |
| 1H21                             | \$84.5m           | \$84.5m                           | \$11.3m               | \$3.9m                         | \$9.7m                      |
| Change (pcp)                     | +22.3%            | +26.5%                            | +26.2%                | +22.1%                         |                             |
| constant currency <sup>(3)</sup> |                   | \$107.1m<br>+27%                  |                       |                                |                             |
| Gross margin <sup>(1)</sup>      | 57.1%             |                                   |                       |                                |                             |
|                                  | +206bps vs pcp    |                                   | Cash position \$58.4m |                                | Operating cash flow +\$2.3m |

BWx's business delivered strong underlying revenue, EBITDA and underlying NPAT growth despite significant global disruption in recent trading environments due to the pandemic.

Strong balance sheet maintained.

Signs of a North American retail-led recovery reflected in USA segment performance (+12% vs pcp), supported by +27% growth in distributions gains delivered in the period vs pcp.

**(1)** Includes 6-month contribution of Flora & Fauna (acquired 01/07/21) and 3-month contribution of Go-To Skincare (acquired 30/09/21). It excludes the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense (refer slide 8 for reconciliation to statutory results). **(2)** non-IFRS measure that excludes \$3.0m of one-off Acquisition-Related Expenses and the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense. **(3)** Constant currency excludes FX translation impact from USD, GBP, CAD, EUR.

# Reconciliation of Underlying to Statutory Earnings



| AUD Million         | Underlying 1H22 | Chemist Warehouse cost of equity | Acquisition costs | Share of Associate Losses | Statutory 1H22 |
|---------------------|-----------------|----------------------------------|-------------------|---------------------------|----------------|
| Revenue             | 106.9           | -3.5 <sup>1</sup>                | -                 |                           | 103.4          |
| Gross Profit        | 61.1            | -3.5                             | -                 |                           | 57.5           |
| Gross Profit Margin | 57.1%           | -                                | -                 |                           | 55.7%          |
| EBITDA              | 14.3            | -3.5                             | -                 |                           | 10.8           |
| EBITDA Margin       | 13.4%           | -                                | -                 |                           | 10.4%          |
| NPAT                | 4.7             | -3.5                             | -3.0 <sup>2</sup> | -0.4                      | -2.3           |

(1) The Chemist Warehouse cost of equity-linked strategic partnership expense, for accounting purposes is a reduction in net revenue. (2) The acquisition costs were one-off costs related Flora & Fauna and to Go-To Skincare




# Statutory NPAT Reconciliation




- 1H22 Statutory NPAT result impacted by \$5.8m related to one-off benefit in 1H21 from the settlement of the Egide Compensation Plan to the sellers of the Andalou Naturals business; \$3.0m in one-off acquisition-related costs; \$3.5m relating to the Chemist Warehouse cost of equity expense that is linked to the strategic partnership that is in place; and \$0.4m relating to share of associate losses

1H21 Statutory to Underlying NPAT



1H22 Statutory to Underlying NPAT



# Operational Highlights



## Connecting to Consumers



Increase in direct-to-consumer (D2C) channel sales, delivering 41% of 1H22 revenues – ahead of 38% target by FY23

- Go-To three-year strategic growth plan established
- F&F integration and realisation of synergy upside
- Additional BWX brand.com sites activated via The Hut Group taking total live sites to 6

Continuing to invest in strategic marketing at 15% of 1H22 net revenues to strengthen and support expanding points of distribution

## Going Global, Going Mainstream



Executing omnichannel distribution strategy globally with 1.6 million total points – on track to achieve 2 million target by 2H22

Demand for core brands continues across key markets and channels

Early indicators of consumption returning to pre-pandemic levels

## Investing In Ourselves



Retaining talent in a highly competitive and challenging labour market and continuing to support employee wellbeing, health & safety

Refresh of company purpose and values enhancing employee value proposition and engagement globally

Executive team supported by lean, agile leadership team

### **New Clayton Facility completed in early 2022 remaining on budget**

- Successfully recouped 10-week construction delay
- Strategic inventory build to support commencement of production and transition

## Getting Clean & Getting Healthy



Strong margin profile sustained across core brands

- Core brand margin<sup>(1)</sup> improved by 334bps vs pcp to 58.5%
- Group Gross Margin<sup>(1)</sup> improved 206bps vs pcp to 57.1%

~\$1m in freight price increases have impacted the business across EBITDA and inventory values but were partially offset with group procurement efficiencies

<sup>(1)</sup> Includes 6-month contribution of Flora & Fauna and 3-month contribution of Go-To Skincare and excludes the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense.

# Segment Performance

| Reported revenue (A\$m)                | 1H21 <sup>(1)</sup> | 1H22            | 1H22 CC <sup>(5)</sup> | Change (pcp) |
|--|---------------------|-----------------|------------------------|--------------|
| Australia/International <sup>(2)</sup> | \$33.3m             | \$41.3m         | \$41.1m                | 24%          |
| Digital <sup>(3)</sup>                 | \$13.4m             | \$19.6m         | \$19.6m                | 47%          |
| USA <sup>(4)</sup>                     | \$37.9m             | \$42.4m         | \$42.8m                | 12%          |
| <b>Total</b>                           | <b>\$84.5m</b>      | <b>\$103.4m</b> | <b>\$103.6m</b>        | <b>22%</b>   |



(1) 1H21 revenue has been restated to reflect change in segment reporting. (2) Australia/International segment includes 3-month contribution of Go-To in 1H22. 1H21 does not include Go-To. 1H22 does not include Nourished Life (3) Digital comprises Nourished Life and Flora & Fauna. 1H21 does not include Flora & Fauna. (4) USA segment also includes Canada (5) 1H22 revenues adjusted for constant currency to exclude FX translation impact from USD, GBP, CAD, EUR.

# Australia/International

sukin®  
AUSTRALIAN • NATURAL

GO-TO

ANDALOU  
NATURALS


BWX

A\$41.3m segment revenue delivered in 1H22  
+24% growth vs 1H21

~642,500 total points of distribution in 1H22 with ANZ  
+11% Asia +37% and UK & EMEA +25% vs pcp, and on  
track to achieve FY22 targets

- Sukin continues global expansion and cycling a very strong pcp performance
- Go-To Skincare in 2Q22 launched the Gro-To range in David Jones Australia and in Bloomingdales, USA
- Andalou Naturals launched in UK

REVENUE CONTRIBUTION BY BRAND



*In Australian Pharmacy Sukin remains the #1 Natural Skincare Brand;  
#8 Total Skincare Brand; and the #1 Natural Haircare brand<sup>(1)</sup>*

*In Australian Grocery Sukin is the clear #1 Natural skincare brand;  
#6 Total Skincare brand; and #2 haircare brands<sup>(1)</sup>*

(1) IRI MarketEdge for the 52 week period ending 16/01/2022




# Digital

A\$19.6m segment revenue delivered in 1H22 up 16.5% vs 1H20

Natural insights engine for market drivers and new product development

- Nourished Life profitability up more than 450% vs pcp as a result of synergy realisation and more effective promotions, as well as improvements in:
  - Average order value at \$95 vs \$89 in pcp
  - Website conversion improved 11.5% vs pcp
  - 18 new brands or 342 SKUs on-boarded during 1H22
- Flora & Fauna cycling a strong sales period with revenue up 3.4% vs pcp or 60% vs 1H20




# USA



A\$42.4m segment revenue delivered in 1H22  
+12% growth vs 1H21

~956,000 total points of distribution in 1H22  
which was 27% higher than pcp and on track  
to achieve FY22 targets

- Evidence of North American retail-led recovery with Andalou Naturals and Mineral Fusion delivering sales growth against the pcp
- Increasing Food, Drug, Mass penetration; Sukin, Andalou Naturals and Mineral Fusion under trial with major USA-based department store



*Andalou Naturals remains the #1 Natural Brand in combined Face Care and Skin Care categories; #5 Haircare and Body Care Brand; and #7 Body Care brand in US Natural Channel<sup>(1)</sup>*

*Mineral Fusion remains the #1 Cosmetics Brand in the US Natural Channel; and #3 Natural Cosmetics Brand in US Conventional Channel<sup>(1)</sup>*




(1) SPINS report in US Natural Channel/US Conventional Channel for the 52-week period ending 23/01/2022

# Brand Highlights




Underlying Revenue<sup>1</sup> (\$m)




**+4.3%**  
vs pcip

Revenue (\$m)




**+5.5%**  
vs pcip

Revenue (\$m)



**+33.3%**  
vs pcip

Revenue<sup>2</sup> (\$m)



**+5%**  
vs pcip

<sup>1</sup>Excludes the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense

<sup>2</sup>BWx ownership was 2Q22 onwards. Comparison included for consistency.

# Financial Summary



Internal use only



# Financial Performance



- Statutory NPAT was **-\$2.3m**, a decrease of **-124.2%** vs 1H21
- Underlying NPAT<sup>(2)</sup> increased by **22.1%** in 1H22 vs 1H21
- Statutory Revenue increased **22.3%** vs pcp to \$103.4m in 1H22
- Underlying Revenue<sup>(1)</sup> increased **26.5%** vs pcp to \$106.9m in 1H22 (\$107.1m constant currency) including recent acquisitions
- Gross Profit Margin<sup>(1)</sup> increased 206 bps to **57.1%**
- Operating Expenses increased by 33.3% due to flow through of acquired businesses and strategic investment across marketing and people across the group during 1H22
- Depreciation & Amortisation has increased by 52.9% driven by acquired businesses and additions of plant and equipment and intangible assets
- Tax Expense in line with expectations and considering specific tax treatment obligations relating to acquisition-related expenses and cost of equity payments during the year

(1) Excludes the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense. (2) Non-IFRS measure that excludes \$3.0m one-off Acquisition-Related Expenses and the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense. (3) Relates to the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense.


| AUD million                        | 1H21       | 1H22        | Change         | CC    | Change |
|------------------------------------|------------|-------------|----------------|-------|--------|
| Revenue <sup>(1)</sup>             | 84.5       | 106.9       | 26.5%          | 107.1 | 26.7%  |
| Gross Profit <sup>(1)</sup>        | 46.5       | 61.1        | 31.2%          |       |        |
| Gross Profit Margin <sup>(1)</sup> | 55.1%      | 57.1%       | 206bps         |       |        |
| Operating Expenses                 | -36.2      | -48.3       | 33.3%          |       |        |
| Other Income                       | 1.0        | 1.5         | 51.2%          |       |        |
| EBITDA <sup>(2)</sup>              | 11.3       | 14.3        | 26.2%          |       |        |
| EBITDA margin <sup>(2)</sup>       | 13.4%      | 13.4%       |                |       |        |
| Cost of Equity <sup>(3)</sup>      | -          | -3.5        | -100.0%        |       |        |
| Acquisition-Related Benefit/(Cost) | 5.8        | -3.0        | -152.2%        |       |        |
| Depreciation & Amortisation        | -3.5       | -5.3        | 52.9%          |       |        |
| Interest Expense                   | -1.4       | -1.5        | 7.2%           |       |        |
| Tax                                | -2.6       | -2.1        | -16.8%         |       |        |
| <b>Reported NPAT</b>               | <b>9.7</b> | <b>-1.7</b> | <b>-117.4%</b> |       |        |
| Statutory NPAT                     | 9.7        | -2.3        | -124.2%        |       |        |
| EPS – Basic                        | 7.2        | -1.5        | -120.8%        |       |        |
| Dividend per share                 | 1.4        | -           |                |       |        |

# Balance Sheet



- **Inventory** increased by **\$20.1m** compared to June 2021 predominately due to transition stock build for the cut over into new manufacturing facility, acquired businesses, and additional safety stock to navigate supply chain disruptions during the period
- **Plant and Equipment** increased by **\$13.8m** compared to June 2021 due to additions relating to the new manufacturing facility
- **Contract Assets and Contract Liabilities** predominantly relates to the cost of equity-linked strategic partnership with Chemist Warehouse
- **Intangibles assets and goodwill** increased by **\$165.0m** mainly due to the acquisitions of Flora and Fauna and Go-To Skincare
- **Trade and other payables** increased by **\$6.2m** compared to June 2021 due to timing of payments and inventory build-up
- **Financial liabilities** increased by **\$32.3m** compared to June 2021 predominantly due to the debt extension for the acquisition of Flora and Fauna
- **Deferred tax liabilities** increased by **\$21.8m** compared to June 2021 due to the recognition of intangible assets from the acquisitions of Flora and Fauna and Go-To Skincare
- **Put Option** liability relates to put options for Go-To Co-founders for periods commencing in year three and on every subsequent anniversary


| AUD million                    | DEC 20       | JUN 21       | DEC 21       | Change       |
|--------------------------------|--------------|--------------|--------------|--------------|
| <b>Assets</b>                  |              |              |              |              |
| Cash                           | 77.7         | 70.5         | 58.4         | -12.1        |
| Trade and other receivables    | 29.0         | 39.4         | 36.3         | -3.1         |
| Inventories                    | 38.9         | 44.0         | 64.1         | 20.1         |
| Prepayments                    | 5.9          | 3.0          | 4.1          | 1.1          |
| Contract Assets                | -            | 3.6          | 4.9          | 1.3          |
| Right of use asset             | 10.2         | 9.0          | 8.7          | -0.3         |
| Plant and equipment            | 8.2          | 19.9         | 33.7         | 13.8         |
| Intangible assets and goodwill | 296.8        | 300.1        | 465.1        | 165.0        |
| Investment in Associates       | -            | 0.9          | 0.4          | -0.5         |
| Other Assets                   | 3.6          | 1.6          | 3.3          | 1.7          |
| <b>Total assets</b>            | <b>470.4</b> | <b>492.0</b> | <b>679.1</b> | <b>187.1</b> |
| <b>Liabilities</b>             |              |              |              |              |
| Trade and other payables       | 32.0         | 39.3         | 45.5         | 6.2          |
| Financial Liabilities          | 58.6         | 52.5         | 84.8         | 32.3         |
| Contract Liabilities           | -            | -            | 1.2          | 1.2          |
| Lease Liabilities              | 12.3         | 10.8         | 10.4         | -0.4         |
| Current tax liabilities        | 1.1          | 6.2          | 8.6          | 2.4          |
| Employee benefits              | 2.0          | 2.3          | 3.3          | 1.0          |
| Deferred tax liabilities       | 27.1         | 22.0         | 43.9         | 21.8         |
| Put Option                     | -            | -            | 93.1         | 93.1         |
| <b>Total liabilities</b>       | <b>133.2</b> | <b>133.2</b> | <b>290.7</b> | <b>157.5</b> |
| <b>Net assets</b>              | <b>337.2</b> | <b>358.8</b> | <b>388.3</b> | <b>29.5</b>  |



# Working Capital Performance

- **Working Capital** maintained to support sales growth together with managing the transition to our new manufacturing facility during Q3
- **Inventory**, when excluding transition stock increase and acquired businesses, grew by 9.7% during 1H22
- **Acquired Businesses** refer to Flora and Fauna and Go-To which were acquired on 1 July 2021 and 30 September 2021 respectively

Working Capital Movements (\$m)



# Cash Flow Reconciliation

- **Operating cash flow of \$2.3m** reflects the strategic inventory build focus relating to the transition to the new manufacturing facility
- **Capital expenditure** in line with expectations and has increased to support plant and equipment requirements relating to the new manufacturing facility
- **Tax payments** are in line with expectations



| AUD million                                      | 1H21       | 1H22       |
|--|------------|------------|
| EBITDA <sup>(1)</sup>                            | 11.3       | 14.3       |
| Working Capital Movements                        | 4.9        | -4.6       |
| Acquisition-Related Payments                     | 0.0        | -0.7       |
| Interest Expense                                 | -1.0       | -1.4       |
| Tax  | -3.9       | -1.7       |
| Chemist Warehouse Cost of Equity (Non-Cash)      | -          | -3.5       |
| Other  | -1.9       | -0.1       |
| <b>Operating Cash Flow</b>                       | <b>9.4</b> | <b>2.3</b> |
| Capital Expenditure - Operational                | -2.8       | -4.4       |
| Capital Expenditure - New Manufacturing Facility | -1.0       | -11.4      |

(1) Non-IFRS measure that excludes one off \$3.0m of Acquisition-Related Expenses and the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense.



# Strategy & Outlook

Internal use only



# Delivering Points of Distribution Globally

- BWX increased total global points of distribution by +21% in 1H22 vs pcp to 1.6 million
- Tracking in line with target for 2 million global points of distribution by the end of FY22
- Dedicated to omnichannel strategy to ensure that the presence of BWX brands is evolving with the shopping habits of consumers



- 203 Global Retail Partnerships (+14% vs FY21)
- 28 Active Markets (FY21: 25)
- 29,318 Retail Stores Worldwide (+57% vs FY21)
- +60 Global E-tailer Partnerships (FY21: 50)
- 24,039 POD Sold Online (+21% vs FY21)
- 17 Owned E-comm Sites Globally (FY21: 12)

# The Rise of the Conscious Consumer Globally



- BWX brands are at the forefront of the clean beauty movement, providing accessible products with natural formulations, sustainable solutions and ethical credentials to consumers following the ever-growing global demand
- Our diversified portfolio of brands are positioned within the right categories to continue benefiting from industry trends supporting an emerging Natural & Organic subset of the ~\$500+ billion Beauty & Personal Care market globally

|                           | PROVEN TRENDS      |                    |                    | GROWING TRENDS       |                                |        | EMERGING TRENDS |                 |                |
|---------------------------|--------------------|--------------------|--------------------|----------------------|--------------------------------|--------|-----------------|-----------------|----------------|
| Market Share of total BPC | 56%                | 43%                | 18%                | 21%                  | 17%                            | 13%    | 13%             | 5%              | 1%             |
| Product Claim             | Free from Parabens | Free from Sulfates | Botanical Extracts | Free from Phthalates | Free from Artificial Fragrance | Humane | Cruelty Free    | Vegan Certified | Bio-Degradable |
| Growth % v. ya            | +3.6%              | +2.5%              | +1.9%              | +11.4%               | +8.1%                          | +14.3% | +27.4%          | +33.3%          | +22.2%         |



# New Facility Transforming Growth Agenda

45-49 McNaughton Road, Clayton

Facility completed early 2022 with manufacturing to commence from April.

Significant automation to support production efficiencies & enhance sustainability commitments.

Expected to deliver 300bps improvement in gross margin in line with business case.



1 of 3 interconnected warehouses



6 robots capable of delivering a pallet of finished goods out of production every 2 minutes




High speed automated production lines  
5x line speed of Dandenong Facility

**4**  
Years<sup>1</sup> expected payback



Research and Development lab



Reception

Fully automated production lines installed and expected to triple throughput, drive per unit cost reduction, and expand margins...

...from nine semi-automatic low speed lines at Dandenong Facility

(1) payback of 4 years from completion in relation to the full capital investment of \$33.7m



# GO-TO Global Growth Plan



- The acquisition of a controlling stake in Go-To Skincare, which completed 30 September 2021, represents a strategically and financially compelling opportunity for BWX to partner with one of Australia's leading skin care companies comprising the Go-To, Bro-To, and Gro-To brands
- Go-To provides BWX with a complementary and diversified product suite, enhanced D2C channel presence, and expansion into the masstige subcategory – both domestically and internationally

## FY22 GROWTH PRIORITIES

- Priority markets identified
- Align operating model for international markets
- Prepare new product launches

## FY23 GROWTH PRIORITIES

- On track to realise \$3m synergy upside
- Optimise manufacturing in Clayton facility and enhance margin
- Continuous improvement of NPD and speed to market

## CHANNEL EXPANSION

- Unlock scale benefits leveraging BWX's e-commerce capability in new markets outside of Australia
- Leverage BWX's existing retail partnerships to enhance international distribution and economies of scale

## MARKET EXPANSION

- Australia
- USA
- UK
- Canada



# Outlook – Focusing on Execution



- BWX anticipates strong underlying revenue and EBITDA growth in full-year FY22 with performance weighted to the second half as per previous years, however, BWX continues to closely monitor the external COVID-impacted trading environment
- Q2 revenue momentum has been maintained
- With a simplified growth strategy, BWX is focused on executing against distribution targets across all channels with an expanded brand portfolio, while optimising financial and operational performance through the Clayton Facility

- As always BWX will continue to reinvest cost savings back into our brands to support longer-term value creation for all shareholders

## 1H22

\$14.3m<sup>1</sup>

UNDERLYING EBITDA

\$106.9m<sup>2</sup>

UNDERLYING REVENUE

## 2H22

### Revenue drivers

- Full 6-month contribution of Go-To, Flora & Fauna
- Nourished Life sales improvement
- Global price increases across core brands
- Points of distribution gains
- New product launches

### Efficiency gains

- De-risked supply chain
- Trade spend optimisation
- Group procurement benefits
- Strategic marketing investment

## FY23

### Revenue drivers

- Organic growth
- Go-To global expansion
- Continued distribution gains
- New product launches

### Efficiency gains

- Manufacturing benefits of our new facility (300bps group margin)
- Group procurement benefits
- Strategic marketing investment
- E-commerce automation

### Sustainability initiatives

- Transition to carbon offset brands
- Continue to improve brand recyclability

(1) Non-IFRS measure that excludes \$3.0m one-off acquisition costs and the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense.

(2) Includes 6-month contribution of Flora & Fauna and 3-month contribution of Go-To Skincare and excludes the \$3.5m Chemist Warehouse cost of equity-linked strategic partnership expense.

# Appendix

Personal use only



# Changes to Segment Reporting

- As a result of recent acquisitions, BWX is making a change to its segment reporting to better align with the Group's new organisational structure and strategic direction
- BWX's operating segments are based on the geographic location where the management of the sale originates, as reviewed by the Chief Operating Decision Maker (defined under AASB 8 Operating Segments)
- The new structure comprises the following reportable segments:
  1. **Australia/International**
  2. **Digital**
  3. **United States of America (USA), includes Canada**
- The creation of a new, separate operating segment – Digital – comprises e-commerce platforms Nourished Life and Flora & Fauna (acquired 01/07/21)
- The Australia/International segment will capture results from Go-To Skincare (acquired 30/09/21)
- BWX previously operated within two reportable segments being United States of America (USA) and Australia/International (all other businesses outside of the USA)
- These changes affect only the composition of segment information and will not impact Group earnings previously reported to the market



# Global Brand Presence

Internal use only

